RCpeptides

5-Amino-1-MQ 100x50mg

5-Amino-1-MQ 100x50mg

NOT FOR HUMAN CONSUMPTION

5-Amino-1MQ is a small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor of the quinolinium class (often used as its water-soluble salt). NNMT catalyzes the SAM-dependent methylation of nicotinamide (NAM) → 1-methylnicotinamide (1-MNA). Inhibiting NNMT conserves cellular SAM, reduces 1-MNA formation, and redirects NAM into the NAD⁺ salvage pathway, thereby raising NAD⁺ and modulating epigenetic methylation status (the “methylation sink” concept). In adipose and liver, this re-wiring has shown anti-obesity and insulin-sensitizing effects in animals. 5-Amino-1MQ is a tool compound—it is not FDA/EMA-approved for any human indication.


Additional Benefits of 5-Amino-1MQ Now Under Investigation

Benefit Key take-aways
1 Anti-obesity efficacy without hypophagia In diet-induced-obese mice, systemic 5-Amino-1MQ reduces body weight and visceral adiposity primarily by increasing energy expenditure and shrinking adipocyte size, with little change in food intake.
Cell Metabolism; iScience
2 Insulin sensitivity & glycaemic control Treatment improves insulin tolerance and fasting glucose, lowers HOMA-IR, and normalizes adipose/liver insulin signalling (Akt phosphorylation).
Diabetes; Metabolism
3 NAD⁺ restoration & sirtuin activity By diverting NAM to salvage, intracellular NAD⁺ rises and SIRT1/SIRT3 activity improves, supporting mitochondrial function and oxidative metabolism.
Nature Communications; The Journal of Biological Chemistry
4 Epigenetic re-programming (methylation-sink reversal) NNMT inhibition preserves SAM/SAH ratio, leading to restoration of histone/DNA methylation marks dysregulated in obesity and fibrosis, with downstream metabolic benefits.
Nature; Cell Reports
5 Lipid profile & hepatic steatosis Animal studies show lower plasma cholesterol/TG, decreased hepatic lipogenesis (↓ SREBP1c/FASN), and reduced liver fat.
Hepatology; Liver International
6 Fibrosis signalling down-shift In adipose and liver, NNMT blockade dampens TGF-β/ECM gene programs (COL1A1, CTGF), suggesting anti-fibrotic potential.
Science Advances; JCI Insight
7 Cancer metabolism (context-dependent) Many solid tumours overexpress NNMT; inhibiting it reduces 1-MNA, restores methylation capacity, and curbs migratory/EMT phenotypes in models—supporting oncology tool-use and hit-to-lead campaigns.
Cancer Research; Nature Cell Biology
8 Cardiometabolic inflammation 5-Amino-1MQ reduces adipose macrophage infiltration and pro-inflammatory cytokines (TNF-α/IL-6), aligning with improved insulin sensitivity.
Cardiovascular Diabetology; Frontiers in Endocrinology
9 Exercise-mimetic mitochondrial effects NNMT inhibition up-regulates oxidative genes (PGC-1α, CPT1) and increases VO₂ in rodents, hinting at partial exercise-mimetic properties.
FASEB Journal; American Journal of Physiology–Endocrinology

2. Molecular Mechanism of Action

2.1 Target Pharmacodynamics

  • Primary target: NNMT (cytosolic), which consumes S-adenosyl-methionine (SAM) to methylate nicotinamide → 1-MNA.

  • Inhibition effects:

    1. ↑ NAD⁺ salvage (NAM → NMN → NAD⁺), boosting sirtuin/oxidative metabolism;

    2. ↑ SAM availability / restored methylation capacity, affecting chromatin and gene expression;

    3. ↓ 1-MNA, altering redox and signalling niches where 1-MNA is active.

2.2 Down-stream Biology

PathwayDetails
NAD⁺/Sirtuins (SIRT1/3)

Functional outcome: ↑ mitochondrial biogenesis, ↑ fatty-acid oxidation, improved insulin signalling

Context: Adipose, skeletal muscle, liver

SAM-dependent methylation

Functional outcome: Re-establishes histone/DNA marks (e.g., H3K27, H3K9), normalizes transcriptional programs

Context: Adipose, liver, tumour stroma

Lipogenesis vs oxidation

Functional outcome: ↓ SREBP1c/FASN, ↑ PPARα/PGC-1α/CPT1

Context: Liver/adipose

Inflammation & ECM

Functional outcome: ↓ NF-κB cytokines, ↓ TGF-β/ECM remodelling

Context: Adipose, liver

Thermogenic cues

Functional outcome: ↑ UCPs/oxidative genes → ↑ energy expenditure

Context: Brown/brite adipocytes


3. Pharmacokinetics

  • Form/route: Commonly used intraperitoneal or subcutaneous in rodents; oral PK in mammals is poorly characterized.

  • Exposure: Reported tissue penetration into adipose and liver; detailed human PK/PD unknown.

  • Half-life/clearance: Not fully defined; likely rapid clearance via hepatic/renal routes typical of small cationic heteroaromatics.

  • Medicinal chemistry: 5-Amino-1MQ is a tool compound; next-generation NNMT inhibitors with improved potency/selectivity/PK are in development.


4. Pre-clinical and Translational Evidence

4.1 Obesity & Insulin Resistance

In diet-induced-obese mice, 5-Amino-1MQ reduced weight and fat mass, improved insulin tolerance, and increased energy expenditure, with histology showing smaller adipocytes and reduced macrophage crown-like structures.

4.2 Hepatic Steatosis & Lipids

Rodent NAFLD models demonstrate lower hepatic triglycerides, reduced de novo lipogenesis, and improved plasma lipid profiles under NNMT inhibition.

4.3 NAD⁺/Epigenetic Coupling

Across adipose and stromal cells, NNMT blockade raises NAD⁺, activates sirtuins, and restores methylation capacity, reversing disease-associated transcriptional signatures.

4.4 Oncology (mechanistic)

NNMT overexpression is linked to poor prognosis and global hypomethylation in several cancers; 5-Amino-1MQ reduces migratory/EMT phenotypes in vitro and sensitizes some models to therapy—data remain pre-clinical.

Evidence quality note: Most efficacy and safety data are animal/cell-based. Human trials with 5-Amino-1MQ have not been published; effects should be considered hypothesis-generating.


5. Emerging Clinical Interests

FieldDetails
Metabolic disease (obesity/NAFLD/T2D)

Rationale: Dual NAD⁺ restoration + methylation-sink reversal

Current status: Pre-clinical; candidate optimization

Cardiometabolic risk

Rationale: Lipids, inflammation, adipose remodelling

Current status: Animal data only

Oncology (NNMT-high tumours)

Rationale: Reverse epigenetic/metabolic re-wiring

Current status: Tool-compound studies; novel scaffolds moving forward

Fibrosis

Rationale: ECM down-shift with SAM preservation

Current status: Pre-clinical

Aging/geroscience

Rationale: NAD⁺ axis modulation, inflammaging

Current status: Conceptual/early pre-clinical


6. Safety and Tolerability

  • Human safety: No clinical safety datasets for 5-Amino-1MQ.

  • Pre-clinical: Generally well-tolerated over short courses in rodents; systematic GLP tox not publicly available.

  • Mechanism-based cautions:

    • Methylation biology: Sustained NNMT inhibition alters SAM utilization and epigenetic marks—long-term genomic/epigenomic safety is unknown.

    • NAD⁺ flux: Rapid NAD⁺ shifts can influence sirtuin and PARP activity; theoretical interactions with DNA-repair and redox.

    • 1-MNA signalling: Decreasing 1-MNA may remove vasculoprotective/anti-inflammatory signals reported for that metabolite in specific contexts.

Comparative safety matrix

ConcernDetails
Human data

5-Amino-1MQ (tool NNMTi): None

Next-gen NNMT inhibitors: Early pre-clinical/IND-enabling

NAD⁺ boosters (NR/NMN): Growing (dietary/early trials)

Mechanism

5-Amino-1MQ (tool NNMTi): NNMT block → ↑NAD⁺, ↑SAM

Next-gen NNMT inhibitors: Same, with improved selectivity/PK

NAD⁺ boosters (NR/NMN): ↑NAD⁺ via precursor load

Epigenetic impact

5-Amino-1MQ (tool NNMTi): Direct via SAM conservation

Next-gen NNMT inhibitors: Similar; tunable

NAD⁺ boosters (NR/NMN): Minimal (indirect)

Off-target risk

5-Amino-1MQ (tool NNMTi): Tool-compound level

Next-gen NNMT inhibitors: Optimized (lower)

NAD⁺ boosters (NR/NMN): Low–moderate (metabolic)


7. Regulatory Landscape

  • Status: 5-Amino-1MQ is not approved for human use; appears on research-chemical markets without quality control.

  • Drug development: Multiple proprietary NNMT inhibitor series are in pre-clinical development; no approved NNMT-targeting drugs as of 2025.

  • Use advisory: Any human use outside a trial is unsupported and may carry unknown risk.


8. Future Directions

  • Medicinal chemistry: Improve potency, selectivity, and PK (oral bioavailability, brain/peripheral selectivity).

  • Biomarkers: Develop pharmacodynamic markers (plasma/urine 1-MNA, tissue NAD⁺, SAM/SAH ratio, histone methylation).

  • Indication mapping: Prioritize visceral-obesity/NAFLD phenotypes and NNMT-high tumours with molecular stratification.

  • Combination therapy: Pair with lifestyle or GLP-1/GIP agents (metabolic) or epigenetic/IO drugs (oncology) for synergy.

  • Safety program: Long-term studies on epigenome stability, fertility, and tumour promotion/suppression risk.


Selected References

  • Cell Metabolism; iScience — NNMT inhibition reduces adiposity and increases energy expenditure in obese mice.

  • Diabetes; Metabolism — Improvements in insulin sensitivity and glycaemic control with NNMT blockade.

  • Nature Communications; The Journal of Biological Chemistry — NAD⁺ salvage coupling and sirtuin activation downstream of NNMT inhibition.

  • Nature; Cell Reports — The “methylation sink” role of NNMT and reversal of epigenetic dysregulation.

  • Hepatology; Liver International — Hepatic lipid metabolism and steatosis improvements in NNMT-targeted models.

  • Science Advances; JCI Insight — Anti-fibrotic signatures after restoring SAM/SAH balance.

  • Cancer Research; Nature Cell Biology — NNMT overexpression in cancer and metabolic-epigenetic rewiring; effects of inhibitors on migration/EMT.

  • Cardiovascular Diabetology; Frontiers in Endocrinology — Adipose inflammation and cardiometabolic markers with NNMT inhibition.

  • FASEB Journal; American Journal of Physiology–Endocrinology — Oxidative/thermogenic gene programs and VO₂ changes under NNMT blockade.

For in vitro laboratory research use only. Not for human or veterinary use. Not intended for diagnosis, treatment or prevention of disease.

Price: €160.00

Collection: Powder

Batch test results and COAs

Research use only. Not for human consumption.